Last reviewed · How we verify
YK012
At a glance
| Generic name | YK012 |
|---|---|
| Also known as | YK012 for Injection, YK012 Infusion |
| Sponsor | Excyte Biopharma Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of YK012 in B-cell Acute Lymphoblastic Leukemia (PHASE1, PHASE2)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012 (PHASE1)
- Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus (PHASE1, PHASE2)
- A Phase I Study of YK012 in Primary Membranous Nephropathy (PHASE1)
- Study of YK012 in Primary Membranous Nephropathy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YK012 CI brief — competitive landscape report
- YK012 updates RSS · CI watch RSS
- Excyte Biopharma Ltd portfolio CI